{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(12)"],"submitter":["Kmiecik MJ"],"funding":["Michael J. Fox Foundation for Parkinson's Research","Michael J. Fox Foundation for Parkinson&apos;s Research"],"pubmed_abstract":["<h4>Objective</h4>To examine the associations of LRRK2 p.G2019S, GBA1 p.N409S, polygenic risk scores (PRS), and APOE E4 on PD penetrance, risk, and symptoms.<h4>Methods</h4>We conducted a US-based observational case-control study using data from the 23andMe Inc. and Fox Insight Genetic Substudy (FIGS) databases. The total cohort included 7,586,842 participants (n = 35,163 PD); 8791 LRRK2 p.G2019S carriers (565 with PD), 37,427 GBA1 p.N409S carriers (524 with PD), 244 dual LRRK2/GBA1 carriers (37 with PD), and 7.5 million noncarriers (34,037 with PD). PRS was calculated from the most recently published European genome-wide association study. Survival models estimated the cumulative incidence of PD. Logistic regressions estimated the relative odds of reporting motor and non-motor symptoms ac"],"journal":["Annals of clinical and translational neurology"],"pagination":["2482-2494"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12698958"],"repository":["biostudies-literature"],"pubmed_title":["Genetic Modifiers of Parkinson's Disease: A Case-Control Study."],"pmcid":["PMC12698958"],"pubmed_authors":["Fontanillas P","Norcliffe-Kaufmann L","Riboldi GM","Micheletti S","Hinds DA","Schneider RB","Stagaman K","23andMe Research Team","Holmes MV","Kmiecik MJ","Tat S","Guan A","Tung JY","Aslibekyan S","Shi J","Gottesman J"],"additional_accession":[]},"is_claimable":false,"name":"Genetic Modifiers of Parkinson's Disease: A Case-Control Study.","description":"<h4>Objective</h4>To examine the associations of LRRK2 p.G2019S, GBA1 p.N409S, polygenic risk scores (PRS), and APOE E4 on PD penetrance, risk, and symptoms.<h4>Methods</h4>We conducted a US-based observational case-control study using data from the 23andMe Inc. and Fox Insight Genetic Substudy (FIGS) databases. The total cohort included 7,586,842 participants (n = 35,163 PD); 8791 LRRK2 p.G2019S carriers (565 with PD), 37,427 GBA1 p.N409S carriers (524 with PD), 244 dual LRRK2/GBA1 carriers (37 with PD), and 7.5 million noncarriers (34,037 with PD). PRS was calculated from the most recently published European genome-wide association study. Survival models estimated the cumulative incidence of PD. Logistic regressions estimated the relative odds of reporting motor and non-motor symptoms ac","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T02:13:34.277Z","creation":"2026-05-24T03:12:32.537Z"},"accession":"S-EPMC12698958","cross_references":{"pubmed":["40926580"],"doi":["10.1002/acn3.70176"]}}